T102C polymorphism of the serotonin (5-HT) 2A receptor gene in patients with non-fatal acute myocardial infarction

Atherosclerosis

Volumn 150, Issue 1, 2000, Pages 143-148

  Yamada, Shinichiro ^a   Akita, Hozuka ^a   Kanazawa, Kenji ^a   Ishida, Tatsuro ^a   Hirata, Ken Ichi ^a   Ito, Keiichi ^a   Kawashima, Seinosuke ^a   Yokoyama, Mitsuhiro ^a  

^a KOBE UNIVERSITY   (Japan)

Author keywords

Genetics; Myocardial infarction; Platelet; Risk factors

Indexed keywords

SEROTONIN 2A RECEPTOR; SEROTONIN RECEPTOR;

AGED; ALLELE; ARTICLE; CASE CONTROL STUDY; FEMALE; GENETIC POLYMORPHISM; GENETICS; GENOTYPE; HEART INFARCTION; HUMAN; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION; RISK; RISK FACTOR; STATISTICAL MODEL;

AGED; ALLELES; CASE-CONTROL STUDIES; FEMALE; GENOTYPE; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; ODDS RATIO; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; RECEPTOR, SEROTONIN, 5-HT2A; RECEPTORS, SEROTONIN; RISK FACTORS;

EID: 0034181950     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0021-9150(99)00356-1     Document Type: Article

References (34)

1. DeWood WA, Spores J, Notske R, Mouser LT, Burrough R, Golden MS, et al. Prevalence of total occlusion during the early hours of transmural myocardial infarction. New Engl J Med 1980;303:897-901.
2. Fitzgerald DJ, Roy L, Catella F, Fitzgerald GA. Platelet activation in unstable coronary artery disease. New Engl J Med 1986;315:983-9.
3. Zucker M, Nachmias V. Platelet activation. Arteriosclerosis 1985;5:2-18.
4. Willerson J, Golino P, Eidt J, Campbell W, Buja L. Specific platelet mediators and unstable coronary artery lesions. Circulation 1989;80:198-204.
5. Yokoyama M, Akita H, Mizutani T, Fukuzaki H, Watanabe Y. Hyperreactivity of coronary arterial smooth muscles in response to ergonovine from rabbits with hereditary hyperlipidemia. Circ Res 1983;53:63-71.
6. Awano K, Yokoyama M, Fukuzaki H. Role of serotonin, histamine, and thromboxane A2 in platelet-induced contractions of coronary arteries and aortae from rabbits. J Cardiovasc Pharmacol 1989;13:781-92.
7. Golino P, Piscione F, Willerson JT, Cappelli-Bigazzi M, Chiariello M. Divergent effects of serotonin on coronary artery dimensions and blood flow in patients with coronary atherosclerosis and control patients. New Engl J Med 1991;324:641-8.
8. McFadden EP, Clarke JC, Davies GJ, Kaski JG, Haider AW, Maseri A. Effect of intracoronary serotonin on coronary vessels in patients with stable angina and patients with variant angina. New Engl J Med 1991;324:648-54.
9. Vanhoutte PM. Platelet-derived serotonin, the endothelium and cardiovascular disease. J Cardiovasc Pharmacol 1991;17(suppl. 5):S6-S12.
10. Thulesius O, Lundvall J, Kroese A, Stranden E, Hallbook T, Brunes L, et al. Ketanserin in intermittent claudication: effect on walking distance, blood pressure, and cardiovascular complications. J Cardiovasc Pharmacol 1987;9:728-33.
11. Ketanserin Trial Group. Prevention of atherosclerotic complications: controlled trial of ketanserin. Br Med J 1989;298:424-30.
12. Humphrey P, Hartig P, Hoyer D. A proposed new nomenclature for 5-HT receptors. Trends Pharmacol Sci 1993;14:233-6.
13. Cook W, Fletcher K, Wainwright M, Marks N, Yan S, Leventhal B. Primary structure of the human platelet serotonin 5-HT2A receptor: identity with frontal cortex serotonin 5-HT2A receptor. J Neurochem 1994;63:465-9.
14. Ullmer C, Schmuck K, Kalkman H, Lubbert H. Expression of serotonin receptor mRNA in blood vessels. FEBS Lett 1995;370:215-21.
15. Schmidt CJ, Sorensen SM, Kehne JH, Carr AA, Palfreyman MG. The role of 5-HT2A receptors in antipsychotic activity. Life Sci 1995;56:2209-22.
16. Warren JT, Peacock ML, Rodriguez LC, Fink JK. An Mspl polymorphism in the human serotonin receptor gene (HTR2): detection by DGGE and RFLP analysis. Hum Mol Genet 1993;2:338.
17. Arranz M, Collier D, Sodhi M, Ball D, Roberts G, price J, et al. Association between clozapine response and allelic variation in 5-HT 2A receptor gene. Lancet 1995;346:281-2.
18. Bernard R, Corday E, Eliasch H, Gonin A, Hiait R, Nikolaeva LF, et al. Nomenclature and criteria for diagnosis of ischemic heart disease. Report of the Joint International Society and Federation of Cardiology/World Health Organization task force on standardization of clinical nomenclature. Circulation 1979;59:607-9.
19. Sasaki T, Hattori M, Fukuda R, Kunugi H, Nanko S. 5-HT 2a receptor T102C polymorphism and schizophrenia. Lancet 1996;347:1832.
20. Zhang H, Ishigaki T, Tani K, Chen K, Shih J, Miyasato K, et al. Serotonin 2A receptor gene polymorphism in mood disorder. Biol Psychiatry 1997;41:768-73.
21. Cambien F, Poirier O, Lecerf L, Evans A, Cambou JP, Arveiler D, et al. Deletion polymorphism in the gene for angiotensin converting enzyme is a potent risk factor for myocardial infarction. Nature 1992;359:641-4.
22. Katsuya T, Koike G, Yee TW, Sharpe N, Jackson R, Norton R, et al. Association of angiotensinogen gene T235 variant with increased risk of coronary heart disease. Lancet 1995;345:1600 3.
23. Behague I, Poirier O, Nicaud V, Evans A, Arveiler D, Luc G, et al. β-Fibrinogen gene polymorphisms are associated with plasma fibrinogen and coronary artery disease in patients with myocardial infarction. The ECTIM Study. Circulation 1996;93:440-9.
24. Eriksson P, Kallin B, Hooft FM, Bavenhohn P, Hamsten A. Allele-specific increase in basal transcription of the plasminogenactivator inhibitor 1 gene is associated with myocardial infarction. Proc Natl Acad Sci USA 1995;92:1851-5.
25. Weiss EJ, Bray PB, Tayback M, Schuhnan SP, Kickler TS, Becker LC, et al. A polymorphism of a platelet glycoprotein receptor as an inherited risk factor for coronary thrombosis. New Engl J Med 1996;334:1090-4.
26. Houston D, Shepherd J, Vanhoutte P. Aggregating human platelets cause direct contraction and endothelium-dependent relaxation of isolated canine coronary arteries. J Clin Invest 1986;78:539-44.
27. Kaumann AJ, Frenken M, Posival H, Brown AM. Variable participation of 5-HT1-like receptors and 5-HT2 receptors in serotonin-induced contraction of human isolated coronary arteries. Circulation 1994;90:1141-53.
28. Ishida T, Hirata K, Sakoda T, Kawashima S, Akita H, Yokoyama M. Identification of mRNA for 5HT1 and 5HT2 receptor subtypes in human coronary arteries. Cardiovasc Res 1999;41:267-74.
29. Erdmann J, Shimron-Abarbanell D, Riestschel M, Albus M, Maier W, Korner J, et al. Systematic screening for mutations in the human serotonin-2A (5-HT2A) receptor gene: identification of two naturally occurring receptor variants and association analysis in schizophrenia. Hum Genet 1996;97:614-9.
30. Williams J, Spurlock G, McGuffin P, Mallet J, Nothen MM, Gill M, et al. Meta-analysis of association between schizophrenia and T102C polymorphism of the 5-hydroxytryptamine type 2a-receptor gene. Lancet 1996;347:1294-6.
31. Williams J, McGuffin P, Nothen M, Owen M, Group EC. Meta-analysis of association between the 5-HT 2a receptor T102C polymorphism and schizophrenia. Lancet 1997;349:1221.
32. Yao JK, Kammen DP, Moss HB, Sokulski DE. Decreased serotonergic responsivity in platelets of drug-free patients with schizophrenia. Psychiatry Res 1996;63:123-32.
33. Leysen J, Janssen JP, Megens A, Schotte A. Risperidone: a novel antipsychotic with balanced serotonin-dopamine antagonism, receptor occupancy profile, and pharmacologic activity. J Clin Psychiatry 1994;55(suppl):5-12.
34. Spurlock G, Heils A, Holmans P, Williams JD, Souza U, Cardno A, et al. A family based association study of T102C polymorphism in 5HTR2A and schizophrenia plus identification of new polymorphisms in the promoter. Mol Psychiatry 1997;3:1139-41.